Clostridium difficile associated diarrhea: new rules for an old game

Area of Science:

• Infectious Diseases
• Gastroenterology
• Hospital Epidemiology

Background:

• Clostridioides difficile associated diarrhea (CDAD) is a leading cause of nosocomial diarrhea, with increasing incidence and severity globally.
• A hypervirulent strain, toxinotype III, has emerged, contributing to CDAD's transition from a nuisance to a life-threatening condition.
• CDAD remains under-recognized in India and Asia despite its rising prevalence in Western healthcare settings.

Purpose of the Study:

• To highlight the significance of CDAD as a nosocomial infection.
• To emphasize the importance of early clinical suspicion and diagnostic confirmation of CDAD.
• To outline current therapeutic strategies and preventive measures for CDAD.

Main Methods:

• Clinical suspicion based on diarrhea, fever, and leukocytosis in patients on antibiotics within healthcare settings.
• Confirmation through enzyme-linked immunosorbent assays (ELISA) for C. difficile toxins in stool samples.
• Review of therapeutic approaches including antibiotic therapy, discontinuation of predisposing antibiotics, and supportive care.

Main Results:

• Metronidazole and vancomycin are effective treatments for active CDAD but not for the carrier state.
• Symptomatic recurrence of CDAD occurs in 15%-30% of patients after antibiotic discontinuation.
• Effective control requires a multi-faceted approach including hygiene, personal protective equipment, environmental decontamination, and isolation.

Conclusions:

• Prompt recognition and diagnosis of CDAD are critical, especially in healthcare settings.
• Individualized treatment strategies, primarily involving metronidazole or vancomycin, are essential for managing CDAD.
• Comprehensive infection control measures are vital to prevent and manage healthcare-associated CDAD.